Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

MedXY Editorial Team•Feb 18, 2026•Hematology-Oncology

Access to Patient-Reported Outcome (PRO) data significantly improved inter-rater reliability (ICC) for 13 of 17 symptomatic adverse events in a multinational RCT.
The most substantial improvements in assessment consistency occurred for subjective symptoms such as memory impairment, irritability, and concentration.
The study supports the systematic integration of PROs into oncology clinical trials to mitigate provider under-reporting and improve the accuracy of safety data.
While most symptoms showed improved reliability, some objective symptoms like diarrhea showed unexpected results, suggesting the need for nuanced interpretation of multi-source data.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Access to Patient-Reported Outcome (PRO) data significantly improved inter-rater reliability (ICC) for 13 of 17 symptomatic adverse events in a multinational RCT.
The most substantial improvements in assessment consistency occurred for subjective symptoms such as memory impairment, irritability, and concentration.
The study supports the systematic integration of PROs into oncology clinical trials to mitigate provider under-reporting and improve the accuracy of safety data.
While most symptoms showed improved reliability, some objective symptoms like diarrhea showed unexpected results, suggesting the need for nuanced interpretation of multi-source data.